2nd Quarter - Report

ABBVIE, INC. for ABBVIE INC.

Firm
Client
Income
—
Expenses
$880,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2891, Restoring the America Invents Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

LobbyistCovered position, as disclosed
DORCAS ADEKUNLE —
DANIEL BACHNER —
CRYSTAL RILEY —
STEPHEN SCANGO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2883 (117th), H.R. 2891 (117th), S. 2891 (117th), H.R. 2884 (117th), H.R. 2873 (117th)

Health Issues HCR

H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act H.R. 19, Lower Costs, More Cures Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2022 & 2023; Notice Requirement for Non-Federal Governmental Plans proposed rule Prescription Drug User Fee Act (PDUFA) reauthorization Issues related to the 340B program

LobbyistCovered position, as disclosed
DORCAS ADEKUNLE —
DANIEL BACHNER —
CRYSTAL RILEY —
STEPHEN SCANGO —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; SENATE

Bills named: H.R. 19 (117th), S. 2164 (117th), H.R. 5801 (117th), H.R. 3 (117th), H.R. 5260 (117th)

Medicare/Medicaid MMM

Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F)

LobbyistCovered position, as disclosed
DORCAS ADEKUNLE —
DANIEL BACHNER —
CRYSTAL RILEY —
STEPHEN SCANGO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

H.R.5376, Build Back Better Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

LobbyistCovered position, as disclosed
DORCAS ADEKUNLE —
DANIEL BACHNER —
CRYSTAL RILEY —
STEPHEN SCANGO —

Contacted: Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (117th), H.R. 5376 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.